MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience, Inc. (NAGE)

|||

Balance Sheets Overview

Current Ratio
649.74%
Quick Ratio
512.60%
Debt to Asset Ratio
22.57%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents, inclu...
    • Trade receivables, net of allowa...
    • Intangible assets, net
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents, including restricted cash of 152 for both periods presented
66,740
66,549
64,788
64,290
Trade receivables, net of allowances of 114 and 147, respectively
8,580
13,068
9,741
8,506
Inventories
20,640
24,016
20,424
18,791
Assets held for sale
0
0
541
-
Prepaid expenses and other assets
1,826
1,488
1,312
2,029
Total current assets
97,786
105,121
96,806
93,616
Leasehold improvements and equipment, net
1,247
1,298
1,323
1,499
Intangible assets, net
5,311
5,485
5,660
246
Right-of-use assets, net
1,840
2,019
2,192
2,361
Other long-term assets
405
406
425
417
Total assets
106,589
114,329
106,406
98,139
Accounts payable
9,439
13,277
10,796
12,742
Accrued expenses
3,841
7,621
7,722
8,700
Current maturities of operating lease obligations
917
1,032
1,002
976
Current maturities of finance lease obligations
-
-
0
2
Current deferred consideration liability
524
514
-
-
Customer deposits
329
380
399
292
Total current liabilities
15,050
22,824
19,919
22,712
Deferred revenue
2,434
2,572
2,674
2,674
Operating lease obligations, less current maturities
1,412
1,544
1,815
2,077
Deferred consideration liability, less current portion
5,165
5,059
5,465
-
Total liabilities
24,061
31,999
29,873
27,463
Common stock, 0.001 par value authorized 150,000 shares 78,908 shares and 79,714 shares issued and outstanding at june30, 2026 and december31, 2025, respectively
79
79
79
79
Additional paid-in capital
239,698
240,464
240,991
239,266
Accumulated deficit
-157,247
-158,210
-164,528
-168,660
Cumulative translation adjustments
-2
-3
-9
-9
Total stockholders' equity
82,528
82,330
76,533
70,676
Total liabilities and stockholders' equity
106,589
114,329
106,406
98,139
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents, including...$66,740K (10.36%↑ Y/Y)Inventories$20,640K (43.27%↑ Y/Y)Trade receivables,net of allowances of...$8,580K (-11.14%↓ Y/Y)Prepaid expenses andother assets$1,826K (-14.79%↓ Y/Y)Total current assets$97,786K (12.81%↑ Y/Y)Intangible assets, net$5,311K (1770.07%↑ Y/Y)Right-of-use assets, net$1,840K (-27.13%↓ Y/Y)Leasehold improvementsand equipment, net$1,247K (-23.59%↓ Y/Y)Other long-termassets$405K (0.00%↑ Y/Y)Total assets$106,589K (16.46%↑ Y/Y)Total liabilities andstockholders' equity$106,589K (16.46%↑ Y/Y)Total stockholders'equity$82,528K (28.56%↑ Y/Y)Total liabilities$24,061K (-11.96%↓ Y/Y)Accumulated deficit-$157,247K (9.23%↑ Y/Y)Cumulative translationadjustments-$2K (50.00%↑ Y/Y)Additional paid-in capital$239,698K (0.99%↑ Y/Y)Total currentliabilities$15,050K (-32.59%↓ Y/Y)Deferred considerationliability, less current...$5,165K Deferred revenue$2,434K (-8.98%↓ Y/Y)Operating leaseobligations, less current...$1,412K (-39.37%↓ Y/Y)Common stock, 0.001 parvalue authorized...$79K (0.00%↑ Y/Y)Accounts payable$9,439K (-31.00%↓ Y/Y)Accrued expenses$3,841K (-47.96%↓ Y/Y)Current maturities ofoperating lease...$917K (-4.18%↓ Y/Y)Current deferredconsideration liability$524K Customer deposits$329K (8.58%↑ Y/Y)